¶ Aldosterone
¶ Definition
Aldosterone is a steroid mineralocorticoid hormone synthesized by the adrenal cortex zona glomerulosa that acts as the principal regulator of sodium retention, potassium excretion, and blood volume. It is the terminal effector of the RAA-system, binding Mineralocorticoid Receptor (MR) in distal nephron epithelial cells to upregulate sodium channel expression and drive transcellular sodium reclamation. Beyond its renal effects, aldosterone contributes to vascular inflammation, endothelial dysfunction, and fibrotic remodeling when chronically elevated, linking metabolic stress to cardiovascular disease.
¶ Picture It
Imagine a city's water department during a drought. The mayor (the RAA-system) sends an urgent directive: "Conserve every drop!" Aldosterone is the field supervisor who goes to the water reclamation plant (the kidney's distal tubule) and installs extra pumps (epithelial sodium channels, ENaC) on the filtration line. These pumps pull sodium—and water follows sodium like iron filings to a magnet—back into the city reservoir (bloodstream). For every bucket of water saved, a bucket of potassium waste is dumped out the back door (into urine). This keeps blood volume high and pressure stable.
But here's the problem: if the mayor never cancels the drought alert (chronic stress, Cortisol excess, primary aldosteronism), the supervisor keeps installing more pumps. The reservoir overflows (hypertension), the plumbing corrodes from constant high pressure (vascular fibrosis), and the waste disposal system backs up (hypokalemia, metabolic alkalosis). The pumps themselves become inflammatory—they recruit repair crews (Inflammation, Fibrosis) that patch cracks with scar tissue instead of flexible pipe. What started as an emergency measure becomes chronic damage. In cPNI terms, aldosterone is the selfish endocrine system prioritizing short-term blood pressure survival at the expense of long-term vascular health.
¶ Mechanism
Aldosterone synthesis occurs in the zona glomerulosa of the adrenal cortex via the following cascade:
Synthesis pathway:
- Cholesterol → Pregnenolone (via CYP11A1) → Progesterone (via 3β-HSD) → Deoxycorticosterone (via CYP21A2) → Corticosterone (via CYP11B1) → Aldosterone (via CYP11B2, aldosterone synthase)
- CYP11B2 expression is uniquely stimulated by Ang II (via AT1 receptors), hyperkalemia (K⁺ depolarizes cells, opens Ca²⁺ channels), and to a lesser extent ACTH
Stimuli hierarchy:
- Ang II (via RAA-system) — most potent; acts via AT1 receptors → IP₃/DAG → Ca²⁺ release → CYP11B2 transcription
- Hyperkalemia (K⁺ >5.5 mEq/L) — depolarizes zona glomerulosa cells → voltage-gated Ca²⁺ influx → aldosterone release
- Low sodium (hyponatremia) — indirect; stimulates renin release upstream
- ACTH — minor role; acute stimulation but chronic ACTH does not sustain aldosterone (unlike Cortisol)
Target mechanism in kidney:
- Aldosterone diffuses into principal cells of the distal convoluted tubule and collecting duct
- Binds cytoplasmic Mineralocorticoid Receptor (MR; same receptor that binds Cortisol, but protected by 11β-HSD2 which converts cortisol → cortisone)
- MR-aldosterone complex translocates to nucleus → binds hormone response elements
- Genomic effects (hours): upregulates transcription of:
- ENaC (epithelial sodium channel) subunits α, β, γ
- Na⁺/K⁺-ATPase (basolateral pump)
- Serum and glucocorticoid-regulated kinase 1 (SGK1) — phosphorylates ENaC to increase activity and prevent degradation
- Non-genomic effects (minutes): direct ENaC activation, Na⁺/H⁺ exchanger stimulation
- Net result: ↑ Na⁺ reabsorption from tubular lumen → ↑ water retention → ↑ blood volume → ↑ BP
- Simultaneously: K⁺ secretion via ROMK channels (renal outer medullary potassium channel) and H⁺ secretion via H⁺-ATPase → hypokalemia and metabolic alkalosis if excessive
Extra-renal effects:
- Vascular smooth muscle: MR activation → Reactive Oxygen Species (ROS) production via NADPH oxidase → endothelial dysfunction, stiffness
- Heart: MR activation → pro-fibrotic signaling (TGF-beta, Collagen I/Collagen III deposition) → myocardial fibrosis
- Brain: MR in Hypothalamus and Amygdala → salt appetite, sympathetic activation
- Immune cells: MR activation in macrophages → M1 macrophages polarization, ↑ IL-6, TNF-α
¶ Clinical Significance
Aldosterone dysregulation is a hidden driver in hypertension, heart failure, metabolic syndrome, and chronic kidney disease. In cPNI practice, it exemplifies the selfish endocrine system—the body sacrifices vascular health to maintain short-term blood pressure homeostasis under perceived threat (Allostatic load). Chronic activation of the RAA-system (via chronic stress, insulin resistance, or primary aldosteronism) creates a vicious cycle: high aldosterone → hypertension and vascular damage → kidney injury → more renin release → more aldosterone.
Primary aldosteronism (Conn's syndrome):
- Affects 5-10% of hypertensive patients (far more common than once thought)
- Caused by adrenal adenoma or bilateral adrenal hyperplasia
- Presents with resistant hypertension, hypokalemia (
.5 mEq/L), metabolic alkalosis - Screening: plasma aldosterone concentration (PAC) to plasma renin activity (PRA) ratio >20-30 with PAC >15 ng/dL
- Critical to recognize: standard antihypertensives fail; requires MR antagonists (spironolactone, eplerenone) or adrenalectomy
Secondary aldosteronism:
- Elevated renin drives aldosterone (e.g., renal artery stenosis, heart failure, cirrhosis, chronic stress)
- Common in Metabolic syndrome: insulin resistance → sympathetic activation → renin release → aldosterone
- Cortisol can saturate 11β-HSD2 at high levels (chronic stress) → cortisol activates MR → pseudo-aldosterone excess
Intervention implications:
- MR antagonists (spironolactone 25-100 mg/day, eplerenone 50-100 mg/day): block MR in kidney and vasculature; dramatically reduce cardiovascular mortality in heart failure (RALES trial: 30% mortality reduction)
- Dietary potassium (4.7 g/day target): competes with aldosterone-driven K⁺ loss; independently lowers BP
- Stress reduction (Meditation, HRV training): dampens RAA-system activation via reduced sympathetic tone
- Magnesium supplementation (300-400 mg/day): preserves 11β-HSD2 activity, protecting MR from cortisol occupation
- Salt restriction (<5 g/day): reduces renin-aldosterone drive in salt-sensitive individuals
- ACE inhibitors or ARBs: suppress Ang II-driven aldosterone synthesis upstream
Cross-system connections:
- Metabolic: Aldosterone impairs insulin signaling (MR activation → IRS-1 serine phosphorylation); contributes to Insulin resistance
- Immune: MR activation in macrophages → M1 macrophages polarization → vascular inflammation (Atherosclerosis)
- Neuro: MR in Amygdala and Hypothalamus → salt appetite, stress-induced hypertension
- Gut: High aldosterone → intestinal sodium retention → constipation, altered Gut microbiome (favors salt-tolerant bacteria)
- Evolutionary: The RAA-system evolved for episodic dehydration (hunter-gatherer environments); chronic activation in sedentary, high-salt, high-stress modern life is pure mismatch (Mismatch Disease)
Clinical thresholds:
- Normal plasma aldosterone: 50-150 pg/mL (upright posture, normal salt diet)
- Primary aldosteronism suspect if PAC >15 ng/dL + suppressed renin
- Hypokalemia threshold: .5 mEq/L (but many primary aldosteronism patients normokalemic)
- Urinary aldosterone >12 µg/24h suggests excess (confirmatory test)
¶ Key Facts
- Synthesized exclusively in adrenal zona glomerulosa by CYP11B2 (aldosterone synthase)
- Normal plasma levels: 50-150 pg/mL (upright posture); 10-50 pg/mL (supine)
- Half-life: ~20 minutes; effects last hours due to genomic transcription
- Primary stimuli: Ang II > hyperkalemia >> ACTH (ACTH is not sustained driver)
- 11β-HSD2 enzyme protects MR from Cortisol occupation; deficiency (genetic or licorice ingestion) causes pseudo-aldosteronism
- MR has equal affinity for aldosterone and cortisol; cortisol circulates at 100-1000× higher concentration, so 11β-HSD2 is essential
- Primary aldosteronism prevalence: 5-10% of hypertensive patients; up to 20% of resistant hypertension
- Spironolactone (MR antagonist) reduces heart failure mortality by 30% (RALES trial)
- Chronic aldosterone excess → myocardial and vascular Fibrosis independent of blood pressure (direct MR-mediated TGF-beta signaling)
- Aldosterone increases NLRP3 inflammasome activation in endothelial cells → IL-1β, IL-18 release
- Evolutionary context: aldosterone conserves sodium during dehydration; modern high-salt diets + chronic stress = pathological activation
¶ Connections
- Cortisol — both steroids bind MR; cortisol normally inactivated by 11β-HSD2; chronic stress saturates 11β-HSD2 → cortisol activates MR
- RAA-system — aldosterone is terminal effector; Renin → Ang I → Ang II → aldosterone synthesis via AT1 receptors
- Mineralocorticoid Receptor — aldosterone's nuclear receptor; found in kidney, heart, vasculature, brain, immune cells
- 11β-HSD2 — enzyme that converts cortisol → cortisone in kidney; protects MR from cortisol; deficiency causes pseudo-aldosteronism
- Ang II — primary stimulus for aldosterone synthesis via AT1R → Ca²⁺ → CYP11B2 transcription
- ACE — converts Ang I → Ang II upstream; ACE inhibitors reduce aldosterone indirectly
- Renin — rate-limiting enzyme of RAAS; released by kidney in response to low BP, low Na⁺, sympathetic activation
- Insulin resistance — aldosterone impairs insulin signaling; insulin resistance drives sympathetic tone → renin → aldosterone (vicious cycle)
- Hypertension — aldosterone-driven sodium retention is major contributor; resistant hypertension often primary aldosteronism
- Chronic Kidney Disease — aldosterone causes podocyte injury, glomerulosclerosis, tubulointerstitial fibrosis independent of BP
- Heart failure — chronic aldosterone → myocardial fibrosis, diastolic dysfunction; MR antagonists are cornerstone therapy
- Fibrosis — aldosterone activates TGF-beta signaling in heart, vessels, kidney → collagen deposition
- Inflammation — MR activation in macrophages → M1 macrophages, ↑ IL-6, TNF-α, vascular inflammation
- Reactive Oxygen Species — aldosterone stimulates NADPH oxidase in endothelial cells → ROS → endothelial dysfunction
- Sympathetic nervous system — sympathetic activation (stress, insulin resistance) → renin release → aldosterone; aldosterone also activates sympathetic outflow centrally
- Potassium — aldosterone drives K⁺ secretion via ROMK; chronic excess → hypokalemia (.5 mEq/L) → arrhythmia risk
- Metabolic syndrome — aldosterone links metabolic dysfunction to hypertension; visceral adiposity → insulin resistance → sympathetic drive → RAAS
- Magnesium — Mg²⁺ deficiency impairs 11β-HSD2 → cortisol occupies MR; Mg²⁺ supplementation can lower aldosterone-driven BP
- Allostatic load — chronic aldosterone elevation is biochemical signature of sustained stress; vascular/cardiac damage accumulates
- Selfish brain theory — aldosterone prioritizes brain perfusion pressure (via BP) at expense of vascular health; evolutionary short-term survival vs long-term disease
- Endothelial dysfunction — aldosterone → ROS, ↓ Nitric Oxide, ↑ adhesion molecules → atherosclerosis
- Obesity — adipocytes secrete factors that stimulate aldosterone synthesis (independent of RAAS); visceral fat → aldosterone → hypertension
- Cardiovascular disease — aldosterone is independent risk factor for MI, stroke, arrhythmia; MR antagonists reduce events
¶ Module References
- Module 3 (Neuroendocrinology): Aldosterone as adrenal cortex output
- Neuroendocrinology Walkthrough: Core component of RAAS cascade
- Diagnosis Walkthrough: Aldosterone listed in stress hormone cascade (yellow box) alongside cortisol, adrenaline, noradrenaline, glucagon